Ciprofen Ear Drops

Ciprofen Ear Drops

- Ciprofloxacin   is a fluorinated-4-quinolone or fluoroquinolone
  antibacterial with a wider spectrum of activity than nalidixic acid and
  more favourable pharmacokinetics for use in systemic infection. 
- Ciprofloxacin   is rapidly and well absorbed from the gastro-intestinal
  tract. Oral bioavailability is approximately 70% and a peak plasma
  concentration of about 2.5 ?g/ml is achieved 1 to 2 hours after a dose of
  500 mg by mouth. Absorption may be delayed by the presence of food but not substantially affected overall. 
- The plasma half life is about 3.5 to 4.5 hours, may be prolonged in severe renal failure. 
- Plasma protein binding ranges from 20 to 40%. 
- Ciprofloxacin   is widely distributed in the body, it crosses the placenta and is distributed into breast milk, and high concentrations are achieved in bile. 
- Approximately 40 to 50% of an orally administered dose is excreted in urine as unchanged drug.

* Each film coated tablet CIPROFIN® 750 contains:
   Ciprofloxacin   750 mg  (as Ciprofloxacin   HCl USP)
* Each film coated tablet CIPROFIN® 500 contains:
   Ciprofloxacin   500 mg  (as Ciprofloxacin   HCl USP)
* Each film coated tablet CIPROFIN® 250 contains:
   Ciprofloxacin   250 mg  (as Ciprofloxacin   HCl USP)

- CIPROFIN® is contra-indicated in patients with a history of hypersensitivity to Ciprofloxacin   or other quinolone derivatives. 
- Epileptics and patients with pre-existing CNS lesions. 
- Children, adolescent, pregnant or breast-feeding mothers.

- Fluroquinolones are known to inhibit hepatic drug metabolism and may interfere with the clearance of drugs metabolized by the liver such as theophylline.
- On the other hand, Antiacids, Cations like aluminum, magnesium, or iron reduce the absorption of CIPROFIN® and related drugs when given concomitantly.

- CIPROFIN® should be used during pregnancy only if clearly needed. 
- CIPROFIN® is excreted in breast milk and should be used with caution in lactating mothers.

As with other quinolones, side effects are usually: 
- Gastro-intestinal disturbances include: nausea, vomiting, diarrhoea,
  abdominal pain and dyspepsia. 
-  CNS disturbances:Headache, dizziness and restlessness .
- Hypersensitivity type reactions affecting the skin, in addition to rash and pruritus.

- CIPROFIN® should be used with caution in patients with epilepsy or  a history of CNS disorders, and to those with impaired renal or hepatic functions, glucose-6-phosphate dehydrogenase deficiency and diabetes.
- During treatment, patients should not expose themselves to sunlight, UV  rays or sunray lamp (due to photosensitivity reactions.) 
- Avoid driving or other activities requiring alertness. 
- Antacid or iron should not be taken within 2 hours of intake of CIPROFIN® .

CIPROFIN® Film coated tablet 750 mg
    (Blisters of 10 Tablets, Pack of one blister)
CIPROFIN® Film coated tablet 500 mg
    (Blisters of 10 Tablets, Pack of one blister) 
CIPROFIN® Film coated tablet 250 mg
    (Blisters of 10 Tablets, Pack of one blister)

Store in a dry place at a temperature below  25o C.